January 13, 2014
Nuvilex Making Great Strides in Medical Marijuana Initiatives
In the 21st century, certain initiatives have moved so far and so fast that they have tend to take on a life of their own. This is clearly the case with marijuana in early 2014, now that the nation has overwhelmingly changed its stance toward the broad and widespread use of Cannabis. Driven by its own steps in recent weeks, Nuvilex, Inc.’s (OTCQB – NVLX - $0.12 – Spec Buy) medical marijuana initiatives may take center stage for a spell, and rightfully so, given the shift in sentiment by consumers and investors alike.
For example, in the past week, the state of Colorado has legalized the sale of marijuana for recreational use, and others may elect to do so as well. Colorado expects to earn nearly $70M in annual tax revenue this year and now the state of Maryland has a legislator that believes he can get a similar bill passed. Plus, New York has now passed a medical marijuana law of its own, joining 20 other states. Moreover, a recent CNN/ORC International poll found that fully 55% of all Americans believe that marijuana should be legal. These events are not unrelated and their correlation illustrates the recent rise in interest and driver of stocks with exposure to the space in the capital markets along with a major rise in the development and use of medical marijuana as well as the use of marijuana for recreational purposes.
At the end of 2013, Nuvilex’s subsidiary, Medical Marijuana Sciences, Inc., announced that it appointed Dr. Mark L. Rabe, a leading figure in the field, as Chairman of its Scientific Advisory Board. Dr. Rabe was Chief Medical Officer of California's largest network of physician-owned medical cannabis evaluation centers. In that position, he helped provide over 100,000 medical Cannabis recommendations to patients in 20 different clinics across the state.
Dr. Rabe hired and trained medical personnel, organized public educational symposia and media outreach. Dr. Rabe is also the founder and medical director of Centric Wellness, a medical practice in San Diego that offers natural health care services to attain optimal health and manage chronic medical conditions.
In addition, Nuvilex recently announced that Richard M. Hyslop, Ph.D. has agreed to join the Scientific Advisory Board of Medical Marijuana Sciences, Inc. as well. Dr. Hyslop, Professor of Chemistry and Biochemistry at the University of Northern Colorado, is the first member of the Scientific Advisory Board recruited by the Board's Chairman, Mark L. Rabe, MD. Dr. Hyslop obtained his Ph.D. degree in biochemistry from the University of Texas. His areas of expertise include anti-cancer drug design, the metabolism of anti-cancer drugs and studies of enzymes and enzyme-catalyzed reactions in biological tissues.
Dr. Hyslop's experience with cancer drugs and enzymology could prove to be invaluable in pursuing the goals of Medical Marijuana Sciences that include developing treatments, which employ constituents of Cannabis together with the Cell-in-a-Box™ cellulose-based live-cell encapsulation technology, whose rights were acquired by Nuvilex in 2013, for some of the deadliest forms of cancer. Dr. Hyslop’s location in the most high profile state in the country that has legalized the use of marijuana for medicinal purposes could be a further boon to the Company’s R&D efforts.
With the addition of these two figures, Nuvilex appears to be methodically building a strong foundation in the medical marijuana space with some of the leading experts in the field; this could ultimately position the Company to emerge as a leader in the multi-billion dollar marijuana industry.
For more information, refer to our previous sponsored NVLX Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com
You Might Also Like
Senior Analyst: Robert Goldman
This Opportunity Research Hot Topics article was prepared for informational purposes only.
Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select format reflects the Firm’s internally generated stock ideas along with economic and stock market outlooks. Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored micro cap research ideas that typically carry greater risks than those stocks covered in the Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research on stocks in the Opportunity Research format typically have a higher risk profile, and may offer greater upside.
Since April 2013, Goldman Small Cap Research has been compensated $500 per article by a third party. This article is the opinion of Goldman Small Cap Research and was written based upon publicly available information. The Company has not endorsed or compensated Goldman Small Cap Research for this article. All information contained in these articles was derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com